| ₹ crore | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Revenue | 3,080 | 2,410 | +27.8% |
| EBITDA | 1,255 | 729 | +72.2% |
| EBITDA margin | 40.8% | 30.3% | +10.5 pts |
| Profit before tax | 1,180 | 733 | +61.0% |
| Net profit | 902 | 545 | +65.5% |
| EPS | ₹33.95 | ₹20.49 | +65.7% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 2,53,300 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 128 | 128 | 415 | 363 | 170 | ||
| — | — | 873 | — | — | ||
| 0.0 | 0.0 | 2.0 | 0.0 | 0.0 | ||
| 2,53,172 | — | — | — | — | ||
| 11,230 | 10,560 | 9,360 | 7,845 | 7,768 | ||
| — | +12.8% | +19.3% | +1.0% | — | ||
| 3,967 | 3,441 | 2,968 | 2,205 | 2,368 | ||
| 35.3% | 32.6% | 31.7% | 28.1% | 30.5% | ||
| 3,483 | 2,978 | 2,566 | 1,827 | 2,025 | ||
| 2,925 | 2,568 | 2,191 | 1,600 | 1,823 | ||
| 26.0% | 24.3% | 23.4% | 20.4% | 23.5% | ||
| ₹110.38 | ₹96.91 | ₹82.68 | ₹60.38 | ₹68.81 | ||
| — | +17.2% | +36.9% | −12.3% | — | ||
| — | 2,738 | 1,653 | 1,261 | 2,460 | ||
| — | −2,520 | −1,438 | −1,003 | −473 | ||
| 218 | 218 | 215 | 258 | 1,987 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 2,53,300.3 | |
| - Cash, Equiv & ST Investments | 169.7 | 363.0 | 415.0 | 128.0 | 128.0 | |
| + Minority Interest | — | — | 873.0 | — | — | |
| + Total Debt | 0.0 | 0.0 | 2.0 | 0.0 | 0.0 | |
| Enterprise Value | — | — | — | — | 2,53,172.3 | |
| Revenue | 7,767.5 | 7,845.0 | 9,360.0 | 10,560.0 | 11,230.0 | |
| Growth %, YoY | — | +1.0 | +19.3 | +12.8 | — | |
| EBITDA | 2,367.8 | 2,205.0 | 2,968.0 | 3,441.0 | 3,967.0 | |
| Margin % | 30.48 | 28.11 | 31.71 | 32.59 | 35.33 | |
| EBIT | 2,024.6 | 1,827.0 | 2,566.0 | 2,978.0 | 3,483.0 | |
| Net Income | 1,823.4 | 1,600.0 | 2,191.0 | 2,568.0 | 2,925.0 | |
| Margin % | 23.47 | 20.40 | 23.41 | 24.32 | 26.05 | |
| EPS, Adj (current shares) | 68.81 | 60.38 | 82.68 | 96.91 | 110.38 | |
| Growth %, YoY | — | -12.3 | +36.9 | +17.2 | — | |
| Cash from Operations | 2,459.7 | 1,261.0 | 1,653.0 | 2,738.0 | — | |
| Capital Expenditures | -473.0 | -1,003.0 | -1,438.0 | -2,520.0 | — | |
| Free Cash Flow | 1,986.7 | 258.0 | 215.0 | 218.0 | 218.0 | |
Prices at the 29 October 2026 close · figures from the company's filings with NSE
Divi's Laboratories (NSE: DIVISLAB) had a market capitalisation of ₹2,56,096 crore at the 29 October 2026 close (₹9,664.00 a share), a PE ratio of 87.6 on the last four quarters' profit and a price-to-book ratio of 15.28. In FY26 its consolidated net profit was ₹2,568 crore on revenue of ₹10,560 crore; in Q1 FY27 (April–June 2026) it was ₹902 crore, up 65.5% year on year. It had no borrowings on 31 March 2026. Promoters held 51.88% of the shares on 30 September 2026.
Divi's Labs' PE ratio is 87.6 at the 29 October 2026 close (₹9,664.00 a share): a market capitalisation of ₹2,56,096 crore divided by consolidated net profit of ₹2,925 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹2,568 crore) it is 99.7.
Divi's Labs' net worth — shareholders' equity in its consolidated balance sheet — was ₹16,761 crore on 31 March 2026, up 12.0% from ₹14,969 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹2,56,096 crore at the 29 October 2026 close.
Divi's Labs' book value per share was ₹632.49 on 31 March 2026: shareholders' equity of ₹16,761 crore divided by the 26.5 crore shares in issue, up 12.0% from ₹564.87 a year earlier. The share price at the 29 October 2026 close was ₹9,664.00.
Divi's Labs' price-to-book (PB) ratio is 15.28 at the 29 October 2026 close: a market capitalisation of ₹2,56,096 crore divided by shareholders' equity (book value) of ₹16,761 crore on 31 March 2026. That is a book value of ₹632.49 per share against a share price of ₹9,664.00.
In FY26, Divi's Labs' return on equity (ROE) was 16.2% and its return on capital employed (ROCE) was 17.8%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 15.4% and ROCE 17.3%.
Divi's Labs' dividend yield is 0.31% at the 29 October 2026 close: dividends of ₹30 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹9,664.00. They were ₹30 on 24 July 2026.
Divi's Labs' market capitalisation was ₹2,56,096 crore (₹2.56 lakh crore) at the 29 October 2026 close: 26.5 crore shares at ₹9,664.00 each.
Yes. Divi's Labs had no borrowings on 31 March 2026 (consolidated balance sheet), and it held ₹3,414 crore of cash, bank balances and current investments.
Divi's Labs' debt-to-equity ratio was 0.00 on 31 March 2026: no borrowings against total equity of ₹16,761 crore. A year earlier, on 31 March 2025, it was 0.00.
Divi's Labs' basic earnings per share (EPS) were ₹96.75 in FY26, against ₹82.53 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹110.21.
In 2026, Divi's Labs has declared one dividend: ₹30 with record date 24 July 2026.
Divi's Labs will announce its Q2 FY27 results (July–September 2026) on Saturday, 7 November 2026, the date of the board meeting it has notified to the exchanges.
Promoters held 51.88% of Divi's Labs on 30 September 2026, unchanged from the previous quarter and down 0.01 percentage points from 51.89% a year earlier, according to the shareholding pattern filed with NSE.
In FY26, Divi's Labs generated ₹2,738 crore of cash from operations and spent ₹2,520 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹218 crore. In FY25 it was ₹215 crore.
Divi's Labs' latest results are for Q1 FY27 (April–June 2026), filed on 1 August 2026: consolidated net profit ₹902 crore, up 65.5% from ₹545 crore in Q1 FY26; revenue from operations ₹3,080 crore, up 27.8% year on year.
On 30 September 2026, Divi's Labs' shares were held by promoters 51.88%, foreign portfolio investors (FII/FPI) 20.38%, domestic institutions (DII) 19.17% (including mutual funds at 14.66%) and retail and other non-institutional investors 8.58%. Over the year, FII holding was up 0.99 percentage points from 19.39% and DII holding was down 0.59 percentage points from 19.76%.
In FY26 (April 2025–March 2026), Divi's Labs' consolidated net profit was ₹2,568 crore, up 17.2% from ₹2,191 crore in FY25, on revenue from operations of ₹10,560 crore (up 12.8%). Over three years, from FY23, net profit was up 40.8%.
In FY26, Divi's Labs earned net profit of ₹2,568 crore on revenue of ₹10,560 crore, against ₹889 crore on ₹6,813 crore for Laurus Labs. Divi's Labs' operating margin was 28.2% (Laurus Labs 19.1%) and its return on equity 16.2% (Laurus Labs 18.2%). At the 29 October 2026 close, Divi's Labs' market capitalisation was ₹2,56,096 crore against ₹1,21,243 crore for Laurus Labs, and its PE ratio on FY26 profit 99.7 against 136.4.
On FY26 consolidated figures, against Laurus Labs, Cohance Lifesciences and Gland Pharma: Divi's Labs' operating margin of 28.2% is the highest of the four (Laurus Labs 19.1%, Cohance Lifesciences 10.6%, Gland Pharma 18.8%; peer average 16.1%); its return on equity of 16.2% is the second highest of the four (Laurus Labs 18.2%, Cohance Lifesciences 6.4%, Gland Pharma 10.5%; peer average 11.7%); its revenue growth over three years of 10.8% a year is the third highest of the four (Laurus Labs 4.1% a year, Cohance Lifesciences 19.2% a year, Gland Pharma 21.1% a year; peer average 14.8% a year).
From Divi's Laboratories' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.